News & Updates

Show Multimedia Only

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

06 Apr 2026 by

Data from two phase III ICONIC-ADVANCE studies presented at AAD 2026 reinforce the potential of the investigational first-in-class targeted oral peptide icotrokinra for the treatment of plaque psoriasis (PsO).

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

06 Apr 2026

What are the risk factors for peritonitis in SLE patients undergoing dialysis?

28 Mar 2026

For patients with systemic lupus erythematosus (SLE) who are undergoing peritoneal dialysis, the risk of peritonitis development may increase with the use of gastric acid suppressants and glucocorticoids and in males, according to a retrospective study.

What are the risk factors for peritonitis in SLE patients undergoing dialysis?

28 Mar 2026

Gout not a risk factor for dementia

17 Mar 2026

Gout does not contribute to an increased risk of overall dementia and may even be protective against Alzheimer's disease (AD) and cognitive impairment, according to the results of a systematic review and meta-analysis.

Gout not a risk factor for dementia

17 Mar 2026

Managing CTD-ILD progression with antifibrotics: Clinical insights and guideline updates

10 Mar 2026 by

Up to 40 percent of patients with connective tissue disease–associated interstitial lung disease (CTD-ILD) develop progressive pulmonary fibrosis, which requires more intensive management beyond immunosuppressants to control the decline in lung function. At the International Conference of Chinese Rheumatologists 2025, Professor Rohit Aggarwal from the Division of Rheumatology, University of Pittsburgh, US, discussed the therapeutic role of nintedanib as an antifibrotic in CTD-ILD management and shared recent updates from international guidelines.

Managing CTD-ILD progression with antifibrotics: Clinical insights and guideline updates

10 Mar 2026

Oral interleukin-1β blocker makes no difference in knee osteoarthritis

10 Mar 2026

Treatment with the oral interleukin-1β blocker diacerein appears minimally beneficial for reducing pain in patients with knee osteoarthritis (OA), as shown in a study.

Oral interleukin-1β blocker makes no difference in knee osteoarthritis

10 Mar 2026

Frailty tied to higher risk of OA incidence, falls

09 Mar 2026

Frailty appears predictive of an increased risk of osteoarthritis (OA) incidence and falls, as well as disease progression, in older adults, a study has shown. However, no association exists between frailty and joint replacement surgery-free time.

Frailty tied to higher risk of OA incidence, falls

09 Mar 2026

Rheumatoid arthritis may induce ILD development

09 Mar 2026 by

Rheumatoid arthritis (RA) appears to contribute to the development of interstitial lung disease (ILD), as shown by genetic evidence from a Mendelian randomization (MR) study.

Rheumatoid arthritis may induce ILD development

09 Mar 2026

RAIL scores identify active LN, predict disease course in adult patients

08 Mar 2026 by

The use of Renal Activity Index for Lupus (RAIL) score helps to detect active lupus nephritis (LN) and to calculate the course of adult LN, suggests a recent study.

RAIL scores identify active LN, predict disease course in adult patients

08 Mar 2026

Hydroxychloroquine shows potential survival benefit in systemic sclerosis

24 Feb 2026

Systemic sclerosis (SSc) patients using hydroxychloroquine have reduced mortality, although they appear to have a higher prevalence of pulmonary hypertension compared with their peers who do not use the drug, according to a retrospective study.

Hydroxychloroquine shows potential survival benefit in systemic sclerosis

24 Feb 2026

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5

20 Feb 2026 by

A 75-year-old male nonsmoker was diagnosed with adult-onset asthma at 54 years old in 2004, with blood eosinophil counts (BEC) rising from 1,500 cells/ μL in 2004 to 1,800 cells/μL in 2006, while serum immunoglobulin E (IgE) remained normal. He tested negative for antineutrophil cytoplasmic antibody (ANCA) and stool ova/cysts.

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5

20 Feb 2026

News & Updates

Showing Rheumatology articles

Showing

Specialty:

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

What are the risk factors for peritonitis in SLE patients undergoing dialysis?

What are the risk factors for peritonitis in SLE patients undergoing dialysis?

Gout not a risk factor for dementia

Gout not a risk factor for dementia

Managing CTD-ILD progression with antifibrotics: Clinical insights and guideline updates

Managing CTD-ILD progression with antifibrotics: Clinical insights and guideline updates

Oral interleukin-1β blocker makes no difference in knee osteoarthritis

Oral interleukin-1β blocker makes no difference in knee osteoarthritis

Frailty tied to higher risk of OA incidence, falls

Frailty tied to higher risk of OA incidence, falls

Rheumatoid arthritis may induce ILD development

Rheumatoid arthritis may induce ILD development

RAIL scores identify active LN, predict disease course in adult patients

RAIL scores identify active LN, predict disease course in adult patients

Hydroxychloroquine shows potential survival benefit in systemic sclerosis

Hydroxychloroquine shows potential survival benefit in systemic sclerosis

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5